Seeking Alpha
28 Nov 2025, 12:30 UTC · 42w ago
Verdict
Headline takes no side. We score CELC +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Gedatolisib demonstrated significant efficacy and a favorable safety profile in Phase 3 VIKTORIA-1 trials for HR+/HER2- advanced breast cancer.
More positive than 99% of claims this week
Celcuity has completed an NDA submission under the FDA's Real-Time Oncology Review (RTOR) program.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 97% of claims this week
The company holds a cash position of $455 million.
So whatStrong liquidity reduces the immediate need for dilutive financing and provides a runway for commercial launch.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported successful Phase 3 trial results, a strong cash position, and is moving toward commercialization.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
10h ago
−16.3%
Price is moving against the score
$84.00 vs $100.35 close before publication (Nov 26) · not market-adjusted
CELC chart →
